Group 1 - The Schall Law Firm has filed a class action lawsuit against BioAge Labs, Inc. for violations of federal securities laws related to its IPO on September 26, 2024 [1] - The lawsuit claims that BioAge made false and misleading statements regarding its lead trial candidate, azelaprag, particularly concerning its safety and potential in obesity therapy [4] - The discontinuation of the STRIDES Phase 2 trial due to safety concerns was contrary to the claims made during the IPO, leading to investor damages when the truth was revealed [4] Group 2 - Investors who purchased BioAge's securities during the IPO are encouraged to contact the Schall Law Firm to discuss their rights [2] - The class in this case has not yet been certified, meaning potential class members are not yet represented by an attorney [3] - The Schall Law Firm specializes in securities class action lawsuits and represents investors globally [5]
BIOA Final Opportunity to Lead BioAge Labs, Inc. Securities Fraud Lawsuit with the Schall Law Firm